Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
Stock Information for Calyxt Inc.
Loading
Please wait while we load your information from QuoteMedia.